Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
Microbial Signature in Adipose Tissue of Crohn's Disease Patients
Crohn's disease (CD) is characterized by compromised immune tolerance to the intestinal commensal microbiota, intestinal barrier inflammation, and hyperplasia of creeping fat (CF) and mesenteric adipose tissue (AT), which seems to be directly related to disease activity. Gut microbiota dysbiosis might be a determining factor in CD etiology, manifesting as a low microbial diversity and a high abundance of potentially pathogenic bacteria. We tested the hypothesis that CF is a reservoir of bacteria through 16S-rRNA sequencing of several AT depots of patients with active and inactive disease and controls. We found a microbiome signature within CF and mesenteric AT from patients, but not in subcutaneous fat. We failed to detect bacterial DNA in any fat depot of controls. Proteobacteria was the most abundant phylum in both CF and mesenteric AT, and positively correlated with fecal calprotectin/C-reactive protein. Notably, the clinical status of patients seemed to be related to the microbiome signature, as those with the inactive disease showed a reduction in the abundance of pathogenic bacteria. Predictive functional profiling revealed many metabolic pathways including lipopolysaccharide biosynthesis and sulfur metabolism overrepresented in active CD relative to that in inactive CD. Our findings demonstrate that microbiota dysbiosis associated with CD pathophysiology is reflected in AT and might contribute to disease severity.
Project:
Instituto de Salud Carlos III PI18/00037
,
Ministerio de Economía y Competitividad PI15/00143
,
Ministerio de Economía y Competitividad PI14/00228
,
Instituto de Salud Carlos III PI17/01503
,
Ministerio de Economía y Competitividad PI15/00256
,
Agencia Estatal de Investigación RTI2018-093919
,
Instituto de Salud Carlos III CB07708/0012
,
Ministerio de Economía y Competitividad RYC2013-13186
,
Ministerio de Ciencia e Innovación CP10/00438
,
Instituto de Salud Carlos III CM18/00029